Replies to post #230702 on Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

I'll say it one more time: Biogen looked at A2-73 carefully and walked away. If they thought Anavex had any chance of success, or saw Anavex as any sort of threat, they'd make an offer shareholders could not refuse. Let's also be clear, if Biogen ever made a serious buyout offer, Missing would have to disclose it because shareholders would have to vote on it.

[Investor2014]

Thorough biochecking, with access to acquaintances who mingle with the upper echelons of biotech investors, shows that A2-73 won't work because 40 years of no results with S1R don't lie. You know much like the experience of removing amyloid plaque.

I think that is the essence of the thesis even by those who are apparently intrigued by the science, but want the CEO replaced to immediately see an enormous jump in SP.

[JWC3]

ANAVEX has promising trial results with A 2-73 in Alzheimer’s and preclinical results in MS.

[Amatuer17]

Why do you think that BIIB will think they are threat? They will be happy to see that there is a drug that works better - with their money and tiny cap of AVXL, they can buy AVXL oof the shelf.

Most BP teams have done good deals and bad deals - but they are not afraid to do deals and take risk.